21.06.2023
Too much caution kills performance
Le Temps - (19.06.2023) - History has shown that it’s often worth taking the plunge into an investment even when some uncertainty remains, provided risk is managed effectively.
Notícias
-
-
24.05.2023
Webinar: the investment consequences of dedollarisation
During our last webinar focusing on the much-discussed idea that more and more countries are abandoning the US dollar as a reserve currency, UBP’s senior strategists shared their thoughts on the combination of cyclical and structural factors that should indeed lead to a weaker dollar, and the impact this will have on asset classes.
-
17.03.2023
Learning from the mistakes of the 1970s
2023 began with market optimism that the US could successfully navigate its battle with inflation. Recent data have confirmed our suspicions that getting inflation back to the Fed’s 2% target will be more challenging than markets had been assuming.
-
-
-
-
-
15.06.2022
Investment Outlook 2022 – mid-year update
The investment landscape has changed substantially in the last six months: conflict has broken out in Ukraine, leading to various geopolitical and social ramifications, and inflationary pressure has been rising and remains a concern across many regions.
-
24.05.2022
“I am not holding my breath for a soft landing”
Finews (19.05.2022) - Financial markets are not about to return to the normality of past years, says Norman Villamin, CIO Wealth Management, to finews.ch.
-
26.04.2022
“The main aim is to avoid any accidents related to rising interest rates”
Le Temps (20.04.2022) - The war in Ukraine has created a highly unusual environment for investors, writes Michaël Lok, Group Chief Investment Officer at UBP.
-
19.01.2022
«The Fed will be selling bonds faster than 2017»
Finanz und Wirtschaft (17.01.2022) - Norman Villamin, CIO Wealth Management of Union Bancaire Privée, expects a radical shift in monetary policy. A tightening cycle is less bad for equities than for bonds and gold, he says.
-
22.11.2021
CRISPR: the implications of gene editing
In the latest episode of UBP’s Expert series, Norman Villamin, CIO Wealth Management and Pierre Corby, Equity Analyst Healthcare, invited Dr Samarth Kulkarni, CEO of CRISPR Therapeutics, to discuss the challenges and investment opportunities offered by medical innovation, specifically in the field of gene editing.
Our latest podcasts
-
Emerging market debt: Where carry meets conviction
Oradores: Thomas Christiansen, Filipe Alves da Silva
-
UBP Family Office Solutions: Guidance from the heart
Oradores: Monica Espinosa, Pierre Ricq
